Table 2.
Results of network meta-analyses.
| Comparison | Analysis 1* | Analysis 2* | Analysis 3* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
| OR (95% CrI) | RRR† (95% CrI) | P(better) | P(best) | OR (95% CrI) | RRR† (95% CrI) | P(better) | P(best) | OR (95% CrI) | RRR† (95% CrI) | P(better) | P(best) | |
| vs placebo | ||||||||||||
| ALEN | 0.81 (0.61– 1.00) | 0.18 (0.00– 0.37) | 97% | 3% | 0.75 (0.59–0.92) | 0.23 (0.07–0.39) | > 99% | 4% | 0.85 (0.47–1.44) | 0.14 (−0.39 to 0.51) | 75% | 6% |
| IBAN | 1.12 (0.70– 1.81) | −0.11 (–0.67 to 0.28) | 29% | 1% | 1.08 (0.46–3.28) | −0.07 (–1.66 to 0.51) | 42% | 4% | 1.17 (0.37–2.50) | −0.16 (−1.20 to 0.61) | 33% | 5% |
| RISED | 0.75 (0.54– 0.93) | 0.23 (0.07– 0.43) | 99% | 7% | 0.76 (0.57–0.96) | 0.22 (0.04–0.40) | > 99% | 4% | 0.69 (0.36–1.09) | 0.29 (−0.08 to 0.62) | 95% | 19% |
| BAZ | 0.44 (0.21– 0.92) | 0.53 (0.08– 0.77) | 98% | 90% | 0.50 (0.36–0.78) | 0.47 (0.20–0.61) | > 99% | 89% | 0.50 (0.24–1.02) | 0.48 (−0.01 to 0.74) | 97% | 70% |
| BAZ vs | ||||||||||||
| ALEN | 0.55 (0.26– 1.21) | 0.43 (−0.19 to 0.72) | 94% | 0.67 (0.45–1.11) | 0.31 (−0.10 to 0.52) | 95% | 0.59 (0.24–1.49) | 0.39 (−0.46 to 0.74) | 88% | |||
| IBAN | 0.40 (0.17– 0.94) | 0.58 (0.05–0.81) | 98% | 0.47 (0.15–1.17) | 0.50 (−0.16 to 0.81) | 95% | 0.43 (0.15–1.56) | 0.55 (−0.52 to 0.83) | 92% | |||
| RISED | 0.59 (0.28– 1.32) | 0.39 (−0.29 to 0.70) | 91% | 0.67 (0.45–1.12) | 0.31 (−0.11 to 0.53) | 95% | 0.73 (0.30–1.84) | 0.26 (−0.78 to 0.68) | 76% | |||
AD, aggregated data; ALEN, alendronate; BAZ, bazedoxifene; FRAX, Fracture Risk Assessment Tool; IBAN, ibandronate; IPD, individual patient data; OR, odds ratio; RISED, risedronate; RRR, relative risk reduction; P(better), probability the intervention is better than comparator.
Analysis 1: Unadjusted comparison based on AD of bisphosphonates and subgroup with a FRAX score of ≥20% for bazedoxifene (N = 24,058); analysis 2: Meta-regression controlling for baseline risk (placebo response) based on AD of bisphosphonates and all FRAX subgroups for bazedoxifene (N = 29,267); analysis 3: Meta-regression controlling for baseline risk (placebo response in bisphosphonate trials and FRAX for bazedoxifme trial) based on AD of bisphosphonates and IPD for bazedoxifene (N = 29,267).
RRR = 1 – relative risk. The relative risk and OR will be similar when the incidence of an event is low, such as with nonvertebral fractures.